D. Boral Capital Reaffirms Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $10.00 price target on the stock. D. Boral Capital's price objective suggests a potential upside of 289.11% from the company's previous close.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, March 25th. Maxim Group assumed coverage on Anixa Biosciences in a report on Friday, March 21st. They set a "buy" rating and a $10.00 target price for the company.

Anixa Biosciences Stock Down 1.5%

Anixa Biosciences stock traded down $0.04 during midday trading on Thursday, reaching $2.57. The stock had a trading volume of 18,463 shares, compared to its average volume of 89,380. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The firm's 50-day moving average price is $2.68 and its 200 day moving average price is $2.80. The firm has a market capitalization of $82.75 million, a PE ratio of -6.59 and a beta of 0.43.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. Equities research analysts expect that Anixa Biosciences will post -0.41 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its holdings in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after buying an additional 3,900 shares in the last quarter. LPL Financial LLC grew its holdings in Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company's stock valued at $100,000 after buying an additional 11,633 shares in the last quarter. Prosperity Wealth Management Inc. purchased a new position in shares of Anixa Biosciences during the fourth quarter worth about $54,000. Focus Partners Wealth purchased a new position in shares of Anixa Biosciences during the fourth quarter worth about $162,000. Finally, Private Advisor Group LLC purchased a new position in shares of Anixa Biosciences during the first quarter worth about $35,000. Hedge funds and other institutional investors own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.